The Food and Drug Administration (FDA) has approved the application of emergency use authorization (EUA) of Pfizer COVID-19 vaccine for children aged 5-11.
This was confirmed by FDA Director-General Eric Domingo during the Laging Handa press briefing on Thursday.
Domingo said that the experts have seen the effectiveness of the US-made vaccine for the pediatric sector and so far, only reported mild adverse reactions.
"‘Yun pong nakitang adverse events du’n sa clinical trial ay very mild lamang po katulad lamang ng ibang bakuna na natatanggap ng ibang bata. So, kaunting siguro po may sinisinat, kaunting pananakit du’n sa area ng injection. Pero wala pong nakitang any unusual or important safety signals para po hindi natin mabigay itong EUA. So, this is being granted today," Domingo said.
However, the FDA official said the COVID-19 vaccine dosage for children will be different from adults.
"Ito po ay mas mababang dosage at hindi lamang po ‘yun, ‘yung concentration din po nung vaccine ay mas mababa din po kaysa du’n sa ginagamit sa adults ngayon,” he stated.
Meanwhile, a EUA has also been issued on the CoVid-19 drug Molnupiravir, particularly the brand Molnarz, which can be used to mild and moderate cases of CoVid-19 in ages 18 and above.
